# Sanofi Ventures

Source: https://onco.cc/companies/sanofi-ventures/  
OnCo record `sanofi-ventures` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sanofi's strategic venture fund, which invests in early biotech and digital health companies before they are ready to partner with or be bought by Sanofi. Cancer-related holdings include the radiopharmaceutical company AdvanCell and the immune checkpoint company Abcuro.

## Summary

Sanofi Ventures describes itself as 'a strategic venture fund' and 'an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire'. It invests 'across all stages of the private company lifecycle, from Seed to Series B and beyond', leading financings and taking board seats in biotech and digital health companies. Its portfolio page includes AdvanCell (a lead-212 radiotherapeutics company advancing a PSMA-targeting radioligand for prostate cancer, which closed a $315 million Series D in July 2026 and has a collaboration with Lilly), Abcuro (anti-KLRG1 antibodies for autoimmune and cancer indications, including ABC015 to reactivate cytotoxic T and NK cells in the tumour microenvironment) and bluebird bio (gene therapy, with an oncology CAR-T collaboration).

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: corporate-venture
- HQ: Cambridge, MA
- Type: investor
- Website: https://www.sanofiventures.com/

## Notes

- Founding year and office address not stated on fetched pages; Cambridge, MA follows the task hint.

## Sources

- Official website: https://www.sanofiventures.com/
- Portfolio: https://www.sanofiventures.com/portfolio/

## Connected records

- companies: [Nucleai](https://onco.cc/companies/nucleai/), [Sanofi](https://onco.cc/companies/sanofi/), [Trial Library](https://onco.cc/companies/trial-library/)

---
JSON: https://onco.cc/api/v1/entities/sanofi-ventures.json